[SFGate] At $1,000 a pill, Sovaldi will bankrupt us

How much can we afford to pay for one drug? How much profit does one company deserve for producing that drug? With last month’s release of record earnings for Gilead Sciences – nearly $6 billion in profits in half a year from the hepatitis C drug, Sovaldi, these questions need to be answered.

[button title=”Read More” link=”http://www.sfgate.com/opinion/openforum/article/At-1-000-a-pill-Sovaldi-will-bankrupt-us-5665750.php” target=”_blank” size=”” color=”” class=””]